31 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22850 | Metastatic, any tumors | Solid tumors | Institut Jules Bordet | IJB_2728 | Trial open for recruitment | Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention | |||||
| 22710 | Metastatic or non-resecable. Refractory to platinum regimen | Alain Hendlisz | Multiple | Institut Jules Bordet | IJB-MULTI-MIME-A-2017 | Trial closed | IJB-MULTI-MIME-A-2017 Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial | alain.hendlisz@hubruxelles.be | 2 | 2 | |
| 22720 | Participated in parent study | Thierry Berghmans | Multiple | Roche | IMBrella | Trial closed for recruitment | An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) | 4 | 4 | ||
| 22849 | Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors | Solid tumors | Intervention destinée aux parents | Trial open for recruitment | L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité | ||||||
| 29410 | Nieves Martinez Chanza | Multiple | Merck | JAVELIN Bladder Medley | Trial open for recruitment | A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy | nieves.martinez-chanza@hubruxelles.be | 2 | 2 | ||
| 22748 | Metastatic. RECIST v1.1 | Thierry Gil | Kidney | UCL St Luc | METASUN UCL-ONCO 2012-09 | Trial open for recruitment | A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma | thierry.gil@hubruxelles.be | |||
| 22815 | Recurrent or persistent or metastatic tumor | Ahmad Hussein Awada | Multiple | MSD (Merck Sharp & Dohme) | MK-3475-012 | Trial closed | A phase Ib multi-cohort study of MK-3475 in subjects with advanced solid tumors | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 28956 | Spyridon Sideris | Kidney | Merck | MK-6482 PN011 | Trial closed for recruitment | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy |
spyridon.sideris@hubruxelles.be | 3 | 3 | ||
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22687 | Metastatic | François-Xavier Otte | prostate | UZ-Gent | PEACE V - STORM | Trial open for recruitment | PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | |
| 22848 | Smoker of quit smoking within the last 6 months, any tumors | Solid tumors | Institut Jules Bordet | Sevrage Tabagique | Trial open for recruitment | Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study | |||||
| 23023 | RECIST v1.1 | Philippe Aftimos | Multiple | Synthon Biopharmaceuticals | SYD985.004 | Trial closed for recruitment | A two-part phase I study with the antibody-drug conjugate SYD985 in combination with niraparib to evaluate safety, pharmacokinetics and efficacy in patients with HER2-expressing locally advanced or metastatic solid tumours | philippe.aftimos@hubruxelles.be | 1 | 1 | |
| 29059 | Spyridon Sideris | prostate | Pfizer | Talapro-3 | Trial closed for recruitment | Talapro-3: A Phase 3, Randomized, Double-Blind, Study Of Talazoparib With Enzalutamide Versus Placebo With Enzalutamide In Men With Ddr Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | spyridon.sideris@hubruxelles.be | 3 | 3 | ||
| 29407 | Spyridon Sideris | Kidney | AVEO PHARMACEUTICALS, INC. | TiNivo-2 | Trial closed for recruitment | A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor | spyridon.sideris@hubruxelles.be | 3 | 3 |